Page 6 - Controlled Release News Today

Scientists have recently assessed that substituting hydroxycholesterol candidates in ionizable nanoparticles could elevate the possibility of messenger RNA (mRNA) delivery to T cells.

A new study has reported some intriguing developments in the tumour-targeting delivery of nanomedicines, thanks to a polymer coating.

The role of nanocrystals in improving drug delivery approaches is explored in this article.

PureTech Announces Annual Results for Year Ended December 31, 2021 - read this article along with other careers information, tips and advice on BioSpace

Investegate announcements from PureTech Health PLC, Glyph: 20x Oral Bioavailability of Buprenorphine

In this article, Sino Biological discusses how stem cells can be used to support and aid cancer therapy and treatment. They discuss different types of stem cells, pathways to target and how to best produce them.

Innovation Center of Nanomedicine (Center Director: Prof. Kazunori Kataoka) announced that a reviw article for nanomedicines in cisplatin-based cancer therapy was accepted by Journal of Controlled Release and published online on March 31, 2022: Y. Han, P. Wen, J. Li and K. Kataoka, J. Controlled Release, 2022, 345, 709-720.

Scientists develop a formulation for the pulmonary administration of siRNA. The aim was to suppress the replication of SARS-CoV-2.

Researchers developed 1,2-dimpalmiyristoyl-sn-glycero-3-phosphocholine liposomes co-loaded with methylprednisolone and N-acetyl cysteine to treat acute respiratory distress syndrome in vivo.

Nanoparticles, the tiny structures, can be utilized to carry substances to a few parts of the body — for instance, to provide a chemotherapy drug to a tumor.